Agreement between Vir Biotechnology and GSK has been revised to study and create treatments for coronaviruses
Image Source:- >> | Content Source:- >> Vir Biotechnology—a San Francisco-based commercial-stage immunology company—stated that their research collaboration agreement with GSK in 2020 has been modified. This modification reflects the fact that Vir will continue its ongoing efforts to discover, innovate, and advance next-generation treatments for COVID-19 and other...